Triple lead cephalic versus subclavian vein approach in cardiac resynchronization therapy device implantation

Julia Vogler1, Anne Geisler2, Nils Gosau1, Samer Hakmi2, Stephan Willems1, Tienush Rassaf3, Reza Wakili3,4 & Elif Kaya3

Cardiac resynchronization therapy (CRT) device implantation is associated with severe complications including pneumo- and hemothorax. Data on a sole cephalic vein approach (sCV), potentially preventing these complications, are limited. The aim of our study was to compare a sole sCV with a subclavian vein approach (SV) in CRT implantations with respect to feasibility and safety. We performed a prospective cohort study enrolling twenty-four consecutive de-novo CRT implantations (group A) using a sCV at two centers. Fifty-four age-matched CRT patients implanted via the SV served (group B) as reference. Procedural success rate and complications were recorded during a follow-up of 4 weeks. All CRTs could be implanted in group A, with 91.7% using cephalic access alone. In group B, CRT implantation was successfully performed in 96.3%. Procedure and fluoroscopy duration were similar for both groups (sCV vs. SV: 119 ± 45 vs. 106 ± 31 minutes, 17 ± 9 vs 14 ± 9 minutes). Radiation dosage was higher in sCV group vs. SV (2984 ± 2370 vs. 1580 ± 1316 cGy*cm², p = 0.001). There was no case of a pneumothorax in group of sCV, while two cases were observed using SV. Overall complication rate was similar (sCV: 13.0% vs. SV: 12.5%). de-novo CRT implantation using a triple cephalic vein approach is feasible. Procedure duration and complication rates were similar, while radiation dosage was higher in the sCV compared to the SV approach. Despite its feasibility in the clinical routine, controlled prospective studies with longer follow-up are required to elucidate a potential benefit with respect to lead longevity.

Cardiac resynchronization therapy (CRT) is an established and guideline recommended therapy in patients with congestive heart failure with severely reduced systolic function and left bundle branch block1. Although implantation techniques and left ventricular (LV) transvenous lead delivery systems have significantly improved, implantation of CRT devices is still associated with complications. These include pneumo- and hemothorax as severe acute complications. In analogy with other transvenous pacemaker or implantable cardioverter defibrillator (ICD) systems lead dysfunction is one of the most common problems during long-term follow-up.

Implantation techniques vary from center to operator and there is no consistent recommendation on a preferred vascular access site for placement of multiple pacing leads required in CRT therapy. Most centers use a combination of cephalic, subclavian, and/or axillary vein access. Since the introduction of peel away sheaths, subclavian vein puncture has been widely used as a primary access for insertion of pacemakers (PM) and ICDs leads due to its simplicity, speed, and high success rate. Based on its low complication rate with respect to hemo- and pneumothoraces, a cephalic vein approach should be routinely intended as a primary vascular access. However, in CRT procedures, requiring a third (LV) lead, the majority of operators use an additional subclavian vein puncture in order to facilitate catheter manipulation for coronary sinus (CS) cannulation and to minimize interaction with the other leads reducing the risk of lead dislodgement. Puncture of the subclavian vein carries a risk of pneumothorax (1–3%) or hemothorax compared to the cephalic vein preparation. The subclavian vein access seems

1Department of Electrophysiology, University Heart Center Hamburg, University Hospital Eppendorf, Hamburg, Germany. 2Department of Cardiovascular Surgery, University Heart Center Hamburg, University Hospital Eppendorf, Hamburg, Germany. 3Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, Essen, Germany. 4German Cardiovascular Research Center (DZHK), partner site: Munich Heart Alliance, Munich, Germany. Correspondence and requests for materials should be addressed to R.W. (email: reza.wakili@uk-essen.de)
to be associated with lead failure and fracture due to the physical entrapment of the lead by the costoclavicular ligament and/or the subclavius muscle (subclavian crush syndrome). Therefore, the option to position all three CRT leads via a single cephalic vein seems to be a potential alternative compared to an additional subclavian access for the LV lead in order to reduce the rate of severe complications. On the other side preparing the cephalic vein and positioning three leads through it requires training and can be technically more challenging potentially resulting in longer procedure times and more blood loss. Little data exist on a sole cephalic vein approach with placement of all three leads via the cephalic vein in patients undergoing CRT pacemaker (CRT-P) and CRT defibrillator (CRT-D) implantation.

The aim of our study was to compare a sole cephalic vein access on an intention-to-treat basis to a subclavian vein access in CRT implantation procedures with respect to feasibility and periprocedural outcome including complication rates.

Methods

Patient enrollment. We performed a prospective cohort study enrolling all consecutive patients between March 2016 and July 2017 undergoing a de-novo three-lead CRT-P or CRT-D implantation on an intention-to-treat basis using a sole cephalic vein (sCV) access for placement of all three leads. This group A represented the sCV approach. The study was performed at two university hospitals, the University Hospital Essen (Department of Cardiology and Vascular Medicine) and the University Heart Center Hamburg (Department of Electrophysiology).

A group n = 54 of age-matched patients served as a control group (group B). All matched patients in this group were implanted during the preceding 18 months in both centers (prior to the consecutive enrollment of the 24 patients in the cephalic vein group) using a subclavian vein access for placement of all three leads.

All patients enrolled in the study fulfilled standard criteria for CRT implantation according to the latest Guidelines of the European Society of Cardiology (ESC) and the AHA/ACCF/AATS/ACR/ASA/SCAI/SCCT/SIR/SVM/SNMMI 2008 Guidelines for the Management of Patients with Suspected or Proven Pericardial Disease and the 1975 Declaration of Helsinki and was approved by the local ethics committee Protocol number 17-7701-BO University of University of Essen).

Procedural workflows. Implant procedures were carried out under conscious sedation or general anesthesia. All patients received perioperative antibiotics.

Triple cephalic vein approach (group A). For the cephalic vein access, incision was performed in the pectoral groove and venous dissection was performed to cannulate the cephalic vein. The first guidewire was inserted via a peripheral venous catheter (size: 18 Gauge) which was then exchanged to a 7 Fr sheath to put in the remaining two guidewires. The 7 Fr sheath was subsequently removed and a 9 Fr sheath was advanced over one of three guidewires to place the right ventricular (RV) lead (in CRT-P a 7 Fr sheath was used). The 9 Fr sheath was slit after the RV lead was in its final position. A 7 Fr sheath was then advanced to implant the right atrial (RA) lead followed by a 9 Fr sheath to place the LV lead. Each sheath was slit prior to adding a new one comparable to a standard subclavian vein approach. A hydrophilic guide wire was only used if we were not able advance the first standard guidewire through the cephalic vein. The sequence of lead placement in the cephalic vein group was RV lead, followed by the RA and finally LV lead.

Our triple cephalic vein approach thus differs from a recently described implantation technique by Hadjis et al. In the largest trial on a triple cephalic vein access (no control group) in CRT 150 of 171 consecutive patients who underwent de novo CRT implantation had all three lead successfully placed via cephalic vein. All implantations were performed by one operator who puts two long hydrophilic guidewires in the cephalic vein and an 11 Fr sheath alongside one of the two wires to advance the 9 Fr RV lead in CRT-D. Two separate sheaths, 9 Fr and 7 Fr, for the right atrial (RA) and LV lead are advanced over the two retained wires after positioning of the RV lead and slitting of the 11Fr sheath. These 9 Fr and 7 Fr sheaths are not slit until the positioning of all three leads is complete in order to avoid lead interactions.

Subclavian vein puncture was not routinely performed unless no target vein could be identified or prepared. Subclavian vein puncture was performed in case of no available cephalic vein or a small cephalic vein prohibiting to implant three leads,

Subclavian vein approach (group B). For the subclavian vein approach, direct puncture of the subclavian vein was performed (Seldinger technique) with separate puncture for each lead (3 punctures in total). Dilators and peel away sheaths were used to advance all pacing and defibrillation leads. Operators implanted RV lead (pacing or ICD) first, then the LV lead and finally the RA lead.

Device implantation. The generator was positioned under the pectoral muscle in all CRT-D patients and over or under the pectoral muscle in CRT-P patients. Procedure duration was defined from the time of skin incision to the time of completion of skin closure, which is routinely recorded in the hospital computer system.

Endpoints. The following procedural parameters were obtained: procedure and fluoroscopy duration, radiation exposure, success rates of the individual strategy as well as sensing and thresholds of each lead. Regarding safety we assessed the following periprocedural complications: pneumothorax or hemothorax with/without drainage, lead dislodgement requiring revision, CS dissection, pericardial effusion, pericardial tamponade, perforation, hematoma requiring evacuation, healing disorders, device/lead infection, major bleeding events.
According to BRAC ≥ 3 criteria. Postprocedural complications as well as sensing and thresholds of each lead were recorded during a follow-up period of 4 weeks. Follow-up in both centers consisted of a routine device interrogation, a chest x-ray and a wound control on day 1 to 3 after implantation during the hospital stay and a device interrogation and wound control 4 weeks after implantation.

Statistical analysis. All data were implemented into a database. Continuous variables are expressed as mean ± standard deviation in case of normal distribution, as median and interquartile range in the case of other distribution. Categorical variables are summarized as counts and percentage. The Mann-Whitney U test was used to compare continuous variables because variables were not normally distributed. Comparisons between the groups were performed using the Pearson’s chi square test or the Fisher’s exact test. An independent statistician performed all analyses using a statistical software package (IBM SPSS version 25, SPSS Inc. an IBM Company, Chicago, IL).

Results
Between March 2016 and July 2017, a total of 78 patients undergoing de-novo CRT implantation were included in the study. Five patients (6.4%) received a CRT-P device and 73 (93.6%) a CRT-D device. Of these, 24 consecutive patients undergoing de-novo CRT implantation were included in a sole cephalic vein access were prospectively enrolled into group A.

Fifty-four age-matched patients served as a control group. These patients were implanted during the 18 months preceding the enrollment of the 24 patients in the group A using a standard approach via the subclavian vein. Baseline characteristics of both groups were similar except for sex, body mass index (BMI) and LV function. The cephalic vein group A showed less male patients (n = 11; 45.8%) compared to the reference group B (n = 41; 75.9%). BMI and LV ejection fraction were both higher in group A compared to the subclavian vein group B (30 ± 5 kg/m² versus 27 ± 5 kg/m²; 29 ± 6% versus 25 ± 7%). Dilative and ischemic cardiomyopathy were equally distributed in group A and B (50.0% versus 48.1% and 25.0% versus 31.5%; p = ns). Patient’s characteristics are summarized in Table 1.

Procedural results. CRT implantation was successfully performed in all 24 patients of the cephalic vein group A. Access via cephalic vein cut-down alone was accomplished in 22 patients. Additional puncture of the subclavian vein for LV lead placement due to a small cephalic vein was required in 1 of the 24 patients, implantation via the subclavian vein alone due to a missing cephalic vein was necessary in another patient.

In the subclavian vein group B, CRT implantation with respect to placement of the LV lead failed in 2 of the 54 patients during the first attempt (3.7%). In one patient, implantation failed due to a periprocedural CS dissection resulting in inability to implant the LV lead. The second implant failure was due to missing LV capture in the target vein (high epicardial LV threshold). The patient received surgical epicardial LV lead placement via left anterior mini-thoracotomy a couple weeks after failure of the transvenous approach resulting in effective biventricular pacing.

The majority of CRT implantations in our study was performed from the left side (100% in the cephalic vein group versus 92.6% in the subclavian vein group; p = ns). Quadripolar LV leads were used in 20 (83.3%) patients in the cephalic vein group and 39 (72.2%) patients in the subclavian vein group (p = ns). Mean procedure duration was slightly shorter when using a subclavian vein approach (119 ± 45 versus 106 ± 31 minutes; p = 0.194) without reaching statistical significance. Fluoroscopy duration was similar in both groups (14 ± 9 versus 17 ± 9 minutes; p = 0.106) (Table 2). Only radiation exposure was significantly higher in the cephalic vein group (2984 ± 2370 versus 1580 ± 1316 cGy·cm²; p = 0.001).

Pacing thresholds of the LV lead (measured at 0.5 ms impulse duration) were similar in both groups at implantation (1.2 ± 0.6 V vs. 1.2 ± 0.5 V, p = 0.311), 24 hours after implantation (1.3 ± 0.7 V vs. 1.2 ± 0.6 V, p = 0.785) and 4 weeks after implantation (1.3 ± 0.7 V vs. 1.2 ± 0.5 V, p = 0.877). As expected, there was no difference in atrial and ventricular pacing thresholds. Long-term follow-up regarding lead performance was not available due to the short-term follow-up of 4 weeks.

| Table 1. Patient baseline characteristics. Data are presented as n (%) or mean ± standard deviation. |
|-----------------------------------------------|
| Total, n = 78 | Cephalic vein group, n = 24 | Subclavian vein group, n = 54 | p−value |
|---------------|-----------------|-----------------|--------|
| Age [years]   | 68 ± 12         | 66 ± 12         | 68 ± 12 | 0.233 |
| Male, n (%)   | 52 (66.7)       | 11 (45.8)       | 41 (75.9) | 0.009 |
| BMI [kg/m²]   | 28 ± 5          | 30 ± 5          | 27 ± 5  | 0.013 |
| Diabetes, n (%) | 27 (34.6) | 9 (37.5) | 18 (33.3) | 0.721 |
| Renal insufficiency, n (%) | 42 (53.8) | 7 (29.2) | 35 (64.8) | 0.004 |
| Atrial fibrillation | 35 (44.9) | 5 (20.8) | 30 (55.6) | 0.004 |
| Prior stroke, n (%) | 11 (14.1) | 1 (4.2) | 10 (18.5) | 0.158 |
| Prior cardiac surgery | 12 (15.4) | 3 (12.5) | 9 (16.5) | 0.745 |
| LVEF (%)      | 26 ± 7          | 29 ± 6          | 25 ± 7  | 0.029 |
| Ischemic cardiomyopathy, n (%) | 23 (29.5) | 6 (25.0) | 17 (31.5) | 0.562 |
| Dilative cardiomyopathy, n (%) | 38 (48.7) | 12 (50.0) | 26 (48.1) | 0.880 |
Periprocedural complications. Periprocedural complications occurred in 10 of 78 patients. There was no difference in the complication rate between patients with three leads implanted via cephalic vein versus those with subclavian vein puncture: In total, complications were noted in three patients (12.5%) in the cephalic vein group and seven patients (13.0%) in the subclavian vein group (Table 3). Lead dislodgement requiring lead reposisioning or replacement was observed in two patients in each group. In addition, one patient in each group experienced a CS dissection during the attempt to implant the LV lead. No pneumothorax was observed in the cephalic vein group A, whereas two pneumothoraces (3.7%) occurred in the subclavian vein group B. Of the two pneumothorax cases one patient required a chest tube. Two further complications were noted in the subclavian group B: one hematoma requiring surgical evacuation in a patient with mechanical mitral and aortic valve pros thesis being on Vitamin K antagonist therapy, and one case of RV lead perforation without significant pericardial effusion resulting in lead repositioning.

Discussion

In our prospective analysis, de-novo CRT implantation could be accomplished in the majority of patients using a sole cephalic vein access. While procedure duration was similar, with a trend to be longer in the cephalic vein group, a sole cephalic vein approach was associated with a higher radiation dosage. Major complications rates did not differ between both groups.

Procedural success. Our procedural results with an implantation success rate of 91.7% for an exclusive cephalic lead implantation are consistent to previous reports, which also evaluated a sole cephalic vein approach for CRT implantation. With respect to the available and provided data, this approach seems feasible and underlies the fact, that a sole cephalic vein approach is possible in de-novo CRT implantations.

While some reports questioning a triple lead approach via the cephalic vein based on its often small diameter other studies describe that it is often not so much the "size" of the vein that predicts a successful implantation via the cephalic vein, but the cephalic anatomy. Especially the course the vein takes to reach the subclavian vein, and the operator’s technique may play an important role. Even a very small cephalic vein with an adequate course to the subclavian vein can be suitable to insert three leads, whereas an adequately sized vein with a suprACLAVICULAR vein may preclude placement of multiple leads.

These latter studies are in line with our data showing success rates >80%. However, the specific techniques facilitating implantation of all three leads through the cephalic vein seem still challenging. This is reflected by the procedural
duration and radiation dosage in our study, which tended or were higher compared to the subclavian access group. In two cases, despite all efforts, we were not successful to implant all three leads via the cephalic vein due to a small cephalic vein in one patient and a missing cephalic vein in another patient. The higher radiation dosage in the cephalic vein group could be well explained by a higher BMI (30 ±5 vs 27 ±5 kg/m²; p =0.013) and less optimized baseline fluoroscopy settings in the cephalic vein group. Fluoroscopy settings in group A (cephalic vein group) were in majority of cases 7.5 pictures/s instead of 3.5 pictures/s which was the mainly used setting in group B. In view of this different variables the observed difference in radiation dosage might be explained in part, but it has still to be considered that the sCV approach could be also associated with a higher radiation dosage. Our procedure duration in both groups correlates favorably with the reported implantation times of a 2013 EHRA survey (implantation time: 60–89 min in 36% of the centers, 90–119 min in 36%, <60 min in 17%, >119 min in 11%)3, which again stresses the point that cephalic vein cut-down might not be associated with longer procedure times, when performed by a trained cephalic vein operator.

Periprocedural complications. The main rationale of our study was to show that a triple cephalic vein approach is feasible and able to reduce short-term complication rates in CRT implantation by mainly eliminating the risk of pneumo- and hemotorax with a modified and simple approach. Randomized CRT trials report a pneumothorax rate of up to 1.7%20. Pneumothorax was indeed the second most common major complication (3.7%) in the subclavian vein group, while this complication was absent in the cephalic vein group in our study. Despite no case of a pneumo- or hemotorax occurred in the sCV group, it has to be mentioned that the group size of the sCV group was smaller compared to the subclavian group. In total, the overall short-term complication rate did not differ between both groups (12.5% vs. 13.0%, p =ns). The overall complication rate in both groups appears to be high compared to a recently published study2, but is comparable to randomized clinical trials ranging from 8 up to 23%20–26. Looking at the complications in detail, we observed a trend towards increased rates of lead dislodgement and CS dissection in the cephalic vein group. While there was no statistical difference, these results point to a higher lead dislodgement in the sCV group might be due to the limitation of low number of patients enrolled in the triple cephalic vein arm compared to the reference group being nearly twice as large. The results suggest that CRT related complications might occur during cephalic vein approach just as often as with subclavian vein puncture and might not as much dependent on the type of vascular access. Our higher lead dislodgement rate compared to other studies raises questions concerning our technique of slitting every sheath after lead placement which is different from the one described by Hadijs et al. However, with no intraoperative lead dislodgement an association with our technique of slitting sheaths seems unlikely.

Mid-term Performance and follow up. In our analysis, atrial and ventricular pacing thresholds were similar for the cephalic and subclavian vein group. The follow-up period was yet too short to evaluate whether a sole cephalic vein access may offer a long-term benefit in biventricular pacing by reducing the rate of lead failure associated with subclavian crush syndrome. Axillary and subclavian vein puncture have been shown to be independent predictors of lead failure in a multicenter study of 3169 Fidelis leads, when compared with cephalic vein access5. The existing data on the relationship of the type of vascular access and the rate of lead failure are inconsistent. A recently published study revealed that the use of axillary vein puncture, not cephalic vein cut-down, independently predicted a lower risk of lead failure compared with subclavian vein puncture underlying the hypothesis of subclavia-associated lead failure5.

Large prospective trials comparing axillary, subclavian and cephalic vein access for CRT implantation are necessary to evaluate whether a triple cephalic vein approach is associated with a lower risk of long-term complications. As mentioned above, short-term complication rates were comparable between cephalic and subclavian vein access in our small cohort. Thus, according to our results and previously published trials the type of vascular access for CRT implantation seems to be at the operator's discretion, when looking at these short-term periprocedural complication rates. If cephalic vein cut-down proves to be superior over subclavian vein puncture with regard to lead longevity or major complication rates in future trials, this approach might be recommended as a first line access in CRT implantation.

Limitations
Our study is a small cohort study with a short-term follow-up of 4 weeks that allows to compare periprocedural complications between a triple cephalic vein access and a primary subclavian vein approach. No statement on a possible benefit regarding major complications or lead longevity with a cephalic vein access is possible based on this data set with limited statistical power. Only patients with cephalic vein cut-down were prospectively enrolled, whereas the control group consisted of patients previously implanted and was twice as large as the cephalic vein group. There was no randomization to a strategy of primary cephalic vein cut-down or primary subclavian vein puncture. In addition, the method of axillary vein puncture was not included in this analysis, which has also been reported to have certain advantages. Nevertheless, despite the limitations in statistical power and the non-randomized design this pilot study provides the basis for the feasibility of a triple cephalic vein CRT implantation concept. It has to be further tested in larger prospective randomized trials for its potential benefits.

Conclusion
CRT implantation using a triple cephalic vein approach is feasible in the majority of patients undergoing de-novo three-lead CRT implantation. Overall complication rate did not differ between cephalic vs. subclavian vein approach in our small patient cohort. Additional larger randomized controlled multicenter studies with long-term follow-up are required to evaluate whether there is a potential benefit of the triple cephalic technique as a first line approach in patients undergoing CRT with regard to safety and lead longevity.

Data Availability
For accessing additional data the senior author can be contacted with respect to specific request.
References

1. Ponikowski, P. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016 37(27), 2129–2200 (2016).

2. Chan, N. Y., Kwong, N. P. & Cheong, A. P. Venous access and long-term pacemaker lead failure: comparing contrast-guided axillary vein puncture with subclavian puncture and cephalic cutdown. Europace. 19(7), 1193–1197 (2017).

3. Rongioni, M. G. et al. Preferred tools and techniques for implantation of cardiac electronic devices in Europe: results of the European Heart Rhythm Association survey. Europace. 15(11), 1664–1668 (2013).

4. Calkins, H. et al. Prospective randomized comparison of the safety and effectiveness of placement of endocardial pacemaker and defibrillator leads using the extrathoracic subclavian vein guided by contrast venography versus the cephalic approach. Pacing Clin Electrophysiol. 24(4 Pt 1), 456–464 (2001).

5. Hadjis, A., Prosetti, R. & Essebag, V. Implantation of cardiac resynchronization therapy devices using three leads by cephalic vein dissection approach. Europace. 19(9), 1514–1520 (2017).

6. Res, J. C. et al. Pneumothorax resulting from subclavian puncture: a complication of permanent pacemaker lead implantation. Neth Heart J. 12(3), 101–105 (2004).

7. Parsonnet, V. & Roelke, M. The cephalic vein cutdown versus subclavian puncture for pacemaker/ICD lead implantation. Pacing Clin Electrophysiol. 22(5), 695–697 (1999).

8. Magney, J. E. et al. Anatomical mechanisms explaining damage to pacemaker leads, defibrillator leads, and failure of central venous catheters adjacent to the sternoclavicular joint. Pacing Clin Electrophysiol. 16(3 Pt 1), 445–457 (1993).

9. Birnie, D. H. et al. Clinical predictors of Fidelis lead failure: report from the Canadian Heart Rhythm Society Device Committee. Circulation. 125(10), 1217–1225 (2012).

10. Gallik, D. M., Ben-Zur, U. M., Gross, J. N. & Furman, S. Lead fracture in cephalic versus subclavian approach with transvenous implantable cardioverter defibrillator systems. Pacing Clin Electrophysiol. 19(7), 1089–1094 (1996).

11. Magney, J. E., Staplin, D. H., Flynn, D. M. & Hunter, D. W. A new approach to percutaneous subclavian venipuncture to avoid lead fracture or central venous catheter occlusion. Pacing Clin Electrophysiol. 16(11), 2133–2142 (1993).

12. Tse, H. E., Lau, C. P. & Leung, S. K. A cephalic vein cutdown and venography technique to facilitate pacemaker and defibrillator lead implantation. Pacing Clin Electrophysiol. 24(4 Pt 1), 469–473 (2001).

13. Ussen, B. et al. Safety and feasibility of cephalic venous access for cardiac resynchronization device implantation. Pacing Clin Electrophysiol. 34(3), 365–369 (2011).

14. Romey-Bouchard, C. et al. Simplified cardiac resynchronization implantation technique involving right access and a triple-glide single introducer approach. Heart Rhythm. 2(7), 714–719 (2005).

15. Brignole, M. et al. ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J. 2013 34(29), 2281–2329 (2013).

16. Epstein A. E., et al. ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2013;61(3)69–75. 2012.

17. Chan, N. Clinical experience of contrast venography guided axillary vein puncture in biventricular pacing R1. International Journal of Cardiology. 92(1), 55–58 (2003).

18. Koletti, T. M. et al. Improved ‘cut-down’ technique for transvenous pacemaker lead implantation. Europace. 12(9), 1282–1285 (2010).

19. Knight, B. P. et al. Clinical predictors of successful cephalic venous access for implantation of endocardial leads. J Interv Card Electrophysiol. 7(2), 177–180 (2002).

20. Van Rees, J. B. et al. Implantation-related complications of implantable cardioverter-defibrillators and cardiac resynchronization therapy devices: a systematic review of randomized clinical trials. J Am Coll Cardiol. 58(10), 995–1000 (2011).

21. Abraham, W. T. et al. Cardiac resynchronization in chronic heart failure. N Engl J Med. 346(24), 1845–1853 (2002).

22. Young, J. B. et al. Combined cardiac resynchronization and implantable cardioversion deﬁbrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA. 299(20), 2685–2694 (2003).

23. Bristow, M. R. et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 350(21), 2140–2150 (2004).

24. Beshai, J. et al. Cardiac-resynchronization therapy in heart failure with narrow QRS complexes. N Engl J Med. 357(24), 2461–2471 (2007).

25. Linde, C. et al. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol. 52(23), 1834–1843 (2008).

26. Moss, A. J. et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 361(14), 1329–1338 (2009).

Author Contributions

J.V., E.K. and R.W. initiated the study. The manuscript was written by J.V., E.K. and R.W., J.V., N.G., H.S., A. G., E.K. and R.W. performed the operations. J.V., E.K., R.W., T.R. and S.W. analyzed and interpreted the data. J.V., E.K., H.S., R.W., T.R. and S.W. reviewed the manuscript.

Additional Information

Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-35994-0.

Competing Interests: The authors declare no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018